Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)

Name: Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
Published: 2026
License: Public Domain

Hudson Biotech · 2026

ClinicalTrials.gov · Datasets · License: Public Domain · 2026

Open Source ↗

blind double glp obesity overweight placebo

obesity, overweight (without type 2 diabetes) with weight-related comorbidities, tirzepatide, ly3298176, dual incretin, gip, glp-1, overweight, weight management, placebo, randomized, double-blind

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 910626
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.